SEC Form 4 · accession 0001493152-18-013786
Adhera Therapeutics, Inc. · ATRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Eric Teague
Officer — Chief Financial Officer
Period of report
Sep 24, 2018
Accepted (ET)
Sep 26, 2018 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000737207
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $0.55 | Sep 24, 2018 | A | 450,000 | A | — | Sep 24, 2028 | common stock | 450,000 | 450,000 | D |
Explanation of responses
- F1Options to purchase 100,000 shares of common stock are exercisable immediately, options to purchase 100,000 shares of common stock shall vest on each of September 24, 2019, September 24, 2020 and September 24, 2021, options to purchase 25,000 shares of common stock shall vest on such date (if any) that the Issuer determines that the "2018 Revenue Target" (as defined in the Employment Agreement dated September 24, 2018 between the Issuer and the reporting person (the "Employment Agreement")) is achieved, and options to purchase 25,000 shares of common stock shall vest on such date (if any) that the issuer determines that the "2018 Stock Price Target" (as defined in the Employment Agreement) has been achieved.